A program using a telemedicine approach to treat hepatitis C in people with opioid use disorder that resulted in the cure of more than…
Hepatitis
A single dose of Precision BioSciences’ investigational gene-editing therapy PBGENE-HBV was well tolerated and showed early signs of antiviral activity among three adults with…
HEPATITIS
NewsDosing complete in Phase 2b trial of AHB-137 for hepatitis B
A Phase 2b clinical trial testing AusperBio’s investigational therapy AHB-137 in people with chronic hepatitis B has completed dosing and is now unblinded,…
HEPATITIS
NewsVirtual clinic for liver diseases opens to US patients
A virtual clinic for liver diseases, including hepatitis, has begun treating patients. The LiverRight Hepatology Clinic offers same-week video visits to adults who…
Babies born extremely prematurely who were given a dose of the hepatitis B virus (HBV) vaccine within a day of being born were not…
HEPATITIS
NewsFDA grants breakthrough designation to hepatitis D treatment
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to brelovitug, a hepatitis D treatment that’s being developed by Bluejay…
Virion Therapeutics has announced that it’s completed enrollment for the first two groups of adults with chronic hepatitis B virus (HBV) infection in…
HEPATITIS
NewsABI-4334 shows promise in hepatitis B Phase 1b trial: Data
Oral therapy ABI-4334 shows potent antiviral activity in adults with chronic hepatitis B virus (HBV) infection, according to interim data from an ongoing Phase…
Tobevibart and elebsiran, an experimental treatment combination that Vir Biotechnology is developing for chronic hepatitis D, has been awarded both breakthrough therapy designation…
A two-month course of an oral antiviral treatment combination of bemnifosbuvir and ruzasvir was well tolerated and led to sustained clearance of the…
Recent Posts
- Alagille Syndrome Awareness Day seeks to unite global community
- Long-term trial results raise hopes for new hepatitis D treatment approach
- Genetic analysis unveils 3 potentially key treatment targets for PSC
- Getting ahead of concerns about fatty liver disease in children
- Early trial results testing maralixibat for hard-to-treat itching due by year’s end